• OPEN AN ACCOUNT
Indian Indices
Nifty
24,967.75 97.65
(0.39%)
Sensex
80,981.06 -654.85
( -0.80%)
Bank Nifty
55,139.30 -10.10
( -0.02%)
Nifty IT
36,280.10 839.25
( 2.37%)
Global Indices
Nasdaq
45,305.71 -347.04
(-0.76%)
Dow Jones
6,460.93 -26.98
(-0.42%)
Hang Seng
42,789.96 156.67
(0.37%)
Nikkei 225
9,321.40 12.20
(0.13%)
Forex
USD-INR
87.34 0.17
(0.20%)
EUR-INR
102.37 0.98
(0.96%)
GBP-INR
118.09 0.93
(0.80%)
JPY-INR
0.59 0.00
(0.82%)

EQUITY - MARKET SCREENER

Citurgia Biochemicals Ltd
Industry :  Chemicals
BSE Code
ISIN Demat
Book Value()
506373
INE795B01031
-0.5292343
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
CITURGIBIO
0
417.95
EPS(TTM)
Face Value()
Div & Yield %
0
2
0
 

Marksans Pharma rises as UK subsidiary gets approval for Metformin Prolonged release tablets
Aug 18,2025
The approval was granted by the UK regulatory authorities, allowing Relonchem to market the widely used anti-diabetic medication in three dosage strengths. Metformin is commonly prescribed for the treatment of type 2 diabetes and is considered a frontline therapy for managing blood glucose levels.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company’s consolidated net profit dropped 34.3% to Rs 58.31 crore despite of 4.97% jump in revenue from operations to Rs 619.98 crore in Q1 FY26 over Q1 FY25.